Correction to: J Immunother Cancer 2019 7:75
https://doi.org/10.1186/s40425-019-0525-0
Following publication of the original article [1], the author reported two errors in the authors affiliations:
1. Dr. Song Cheol Kim should be affiliated to Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery,University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea;
2. Dr. Eun Sung Jun should be affiliated to Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea and to Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery,University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea;
Contributor Information
Wei-Lin Wang, Email: wam@zju.edu.cn.
Song Cheol Kim, Email: drksc@amc.seoul.kr.
Xiang-Min Tong, Email: tongxiangmin@163.com.
Ming-Hai Wang, Email: minghai.wang@ttuhsc.edu.
Reference
- 1.Yao et al. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. Journal for ImmunoTherapy of Cancer. 2019;7:75. doi: 10.1186/s40425-019-0525-0. [DOI] [PMC free article] [PubMed] [Google Scholar]